Aclaris Therapeutics, Inc. - Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K, dated June 4, 2020, details the results of Aclaris Therapeutics, Inc.'s 2020 Annual Meeting of Stockholders. The company is incorporated in Delaware and trades on The Nasdaq Stock Market under the symbol ACRS.
Key Financial Metrics
This filing does not contain financial performance data such as revenue, profit, cash flow, margins, debt, or liquidity. The document is strictly a report on corporate governance voting outcomes.
Material Changes and Voting Results
Of the 41,832,220 shares outstanding, 35,542,031 shares (84.96%) were present or represented by proxy. Two proposals were voted upon:
- Proposal 1: Election of Directors. Three nominees were elected to serve until the 2023 annual meeting.
- Anand Mehra: 23,766,641 votes For; 3,040,555 votes Withheld.
- Andrew Powell: 22,182,336 votes For; 4,624,860 votes Withheld.
- Maxine Gowen: 26,700,205 votes For; 106,991 votes Withheld.
- Broker Non-Votes: 8,734,835.
- Proposal 2: Ratification of Auditors. Stockholders ratified the appointment of PricewaterhouseCoopers LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2020.
- Votes For: 35,416,580.
- Votes Against: 39,185.
- Abstained: 86,266.
Guidance, Outlook, and Risks
The filing does not provide management commentary, financial guidance, outlook, or specific risk factors. It references the definitive proxy statement filed on April 23, 2020, for further details on the proposals.
Key Facts for Investor Verification
- Verify the full text of the April 23, 2020 proxy statement for detailed biographies of the elected directors and the rationale for the auditor appointment.
- Note the significant number of broker non-votes (8,734,835) regarding the director election, which may indicate institutional holdings where brokers lacked discretionary voting power.
- Confirm the tenure of the newly elected directors, which extends until the 2023 annual meeting.